Aurélie Rousseau1, Patrick Van Dreden2, Elisabeth Mbemba1, Ismail Elalamy3, Annette Larsen1, Grigoris T Gerotziafas4. 1. INSERM U938, Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France. 2. Research and Development, Diagnostica Stago, Gennevilliers, France. 3. INSERM U938, Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France; Service d'Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique Hôpitaux de Paris, Paris, France. 4. INSERM U938, Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France; Service d'Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique Hôpitaux de Paris, Paris, France. Electronic address: grigorios.gerotziafas@aphp.fr.
Abstract
INTRODUCTION: Cancer cells may alter the efficiency of the antithrombotic agents. To explore this possibility, the present study compared the capacity of the LMWH enoxaparin and the specific inhibitors of Xa (apixaban and fondaparinux) to inhibit thrombin generation triggered by pancreas adenocarcinoma cells (BXPC3) and human breast carcinoma cells (MCF7). MATERIALS AND METHODS: Samples of platelet poor (PPP) or platelet rich plasma (PRP) spiked with apixaban, fondaparinux or enoxaparin were added in micro wells carrying cancer cells and assessed for thrombin generation. In the control experiment thrombin generation was triggered with tissue factor reagent. RESULTS: The three antithrombotics inhibited thrombin generation in a concentration dependent manner. The BXPC3 and MCF7 cells reversed in a different intensity the effect of the studied agents. According to the histological type of the cancer the antithrombotic efficiency of apixaban was preserved or partially reversed. Fondaparinux, was more vulnerable to the presence of cancer cells as compared to apixaban. The effect of BXCP3 or MCF7 cells on the antithrombotic potency of enoxaparin was of similar magnitude as that on apixaban. CONCLUSIONS: The type of cancer cells is determinant for the antithrombotic efficiency of the specific factor Xa inhibitors. In contrast it does not significantly influence the potency of enoxaparin. The present study shows that the impact of the type of cancer cells on the antithrombotic activity of the specific Xa inhibitors should not be neglected. This has to be taken into consideration for the design of dose-finding studies of the direct orally active FXa inhibitors in patients with different histological types of cancer.
INTRODUCTION:Cancer cells may alter the efficiency of the antithrombotic agents. To explore this possibility, the present study compared the capacity of the LMWHenoxaparin and the specific inhibitors of Xa (apixaban and fondaparinux) to inhibit thrombin generation triggered by pancreas adenocarcinoma cells (BXPC3) and humanbreast carcinoma cells (MCF7). MATERIALS AND METHODS: Samples of platelet poor (PPP) or platelet rich plasma (PRP) spiked with apixaban, fondaparinux or enoxaparin were added in micro wells carrying cancer cells and assessed for thrombin generation. In the control experiment thrombin generation was triggered with tissue factor reagent. RESULTS: The three antithrombotics inhibited thrombin generation in a concentration dependent manner. The BXPC3 and MCF7 cells reversed in a different intensity the effect of the studied agents. According to the histological type of the cancer the antithrombotic efficiency of apixaban was preserved or partially reversed. Fondaparinux, was more vulnerable to the presence of cancer cells as compared to apixaban. The effect of BXCP3 or MCF7 cells on the antithrombotic potency of enoxaparin was of similar magnitude as that on apixaban. CONCLUSIONS: The type of cancer cells is determinant for the antithrombotic efficiency of the specific factor Xa inhibitors. In contrast it does not significantly influence the potency of enoxaparin. The present study shows that the impact of the type of cancer cells on the antithrombotic activity of the specific Xa inhibitors should not be neglected. This has to be taken into consideration for the design of dose-finding studies of the direct orally active FXa inhibitors in patients with different histological types of cancer.
Authors: Marek Z Wojtukiewicz; Dominika Hempel; Ewa Sierko; Stephanie C Tucker; Kenneth V Honn Journal: Cancer Metastasis Rev Date: 2017-06 Impact factor: 9.264
Authors: Cinzia Giaccherini; Marina Marchetti; Giovanna Masci; Cristina Verzeroli; Laura Russo; Luigi Celio; Roberta Sarmiento; Sara Gamba; Carmen J Tartari; Erika Diani; Alfonso Vignoli; Paolo Malighetti; Daniele Spinelli; Carlo Tondini; Sandro Barni; Francesco Giuliani; Fausto Petrelli; Andrea D'Alessio; Giampietro Gasparini; Filippo De Braud; Armando Santoro; Roberto Labianca; Anna Falanga Journal: Haematologica Date: 2019-09-26 Impact factor: 9.941
Authors: Fabio Camacho-Alonso; T Gómez-Albentosa; R E Oñate-Sánchez; M R Tudela-Mulero; M Sánchez-Siles; Francisco J Gómez-García; Yolanda Guerrero-Sánchez Journal: Front Oncol Date: 2020-11-18 Impact factor: 6.244
Authors: Li-Qiao R Ling; Zichen Lin; Rita Paolini; Camile S Farah; Michael McCullough; Mathew A W T Lim; Antonio Celentano Journal: Biology (Basel) Date: 2022-04-14
Authors: Luigina Guasti; Alessandro Squizzato; Paola Moretto; Davide Vigetti; Walter Ageno; Francesco Dentali; Andrea M Maresca; Leonardo Campiotti; Anna M Grandi; Alberto Passi Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240